Q1 EPS Estimates for Haemonetics Increased by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Investment analysts at Zacks Research increased their Q1 2027 earnings estimates for shares of Haemonetics in a research note issued to investors on Monday, November 24th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $1.19 for the quarter, up from their previous forecast of $1.18. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2027 earnings at $1.41 EPS, FY2027 earnings at $5.37 EPS, Q1 2028 earnings at $1.38 EPS and FY2028 earnings at $5.89 EPS.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.15. The business had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.Haemonetics’s revenue was down 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.

Several other equities research analysts also recently commented on HAE. Citigroup dropped their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. BTIG Research restated a “buy” rating and set a $88.00 price target on shares of Haemonetics in a research note on Friday, November 21st. Needham & Company LLC raised their price objective on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Raymond James Financial reissued an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a report on Friday, November 14th. Finally, Mizuho cut their price target on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.70.

Haemonetics Stock Up 0.0%

HAE stock opened at $80.67 on Thursday. The stock has a fifty day moving average of $57.37 and a 200-day moving average of $63.19. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $89.69. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 0.91 and a beta of 0.43. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC raised its position in shares of Haemonetics by 69.3% in the third quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 448 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in Haemonetics in the 3rd quarter worth about $251,000. Danske Bank A S purchased a new stake in shares of Haemonetics in the 3rd quarter valued at about $665,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 837 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of Haemonetics by 3.7% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 35,438 shares of the medical instruments supplier’s stock valued at $1,706,000 after acquiring an additional 1,266 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.